Oncology

The pooled analysis explored outcomes for colorectal cancer patients who were circulating tumor DNA (ctDNA)–ctDNA-positive after surgery, achieved tra...

Results from the phase 3 ACROSS 2 trial (NCT04500717) revealed that aumolertinib plus chemotherapy significantly improved progression-free survival (P...

The ProSense® cryoablation system achieved the highest complete ablation rate compared with alternatives, with 95% of patients with breast cancer bein...

The combination of the MAT2A inhibitor IDE397 and sacituzumab govitrecan-hziy (Trodelvy) displayed promising activity in a small cohort of patients wi...

At the IASLC 2025 World Conference on Lung Cancer (WCLC), results from the phase 3 ALCHEMIST study (NCT02194738) were presented, showing that adjuvant...

The FDA has approved gemcitabine intravesical system (Inlexzo) for patients who have Bacillus Calmette-Guérin-unresponsive, non-muscle-invasive bladde...

Updated findings from the dose-optimization part of a first-in-human phase 1 trial (NCT05599984) showed that ABBV-706, a seizure-related homolog prote...

Bodei, L., Herrmann, K., Schöder, H., Scott, A. M. & Lewis, J. S. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat. R...

We approached 53 of those who were interested and 41 were interviewed (12 had changed their mind or could not be contacted). Participant characteristi...

Background Docetaxel is the most common chemotherapy regimen for several neoplasms, including advanced OSCC (Oral Squamous Cell Carcinoma). Unfortunat...